viewDyadic International Inc

Noble Capital keeps Outperform rating on Dyadic and ratchets up price target to $11

Fresh data supports the potential of the company’s proprietary C1 platform – a fungal expression technology for producing enzymes

Dyadic International Inc -
Noble is raising its stock price target on the biotech to $11 from $9

Analysts at Noble Capital are taking a bet on Dyadic International Inc (NASDAQ:DYAI) and are sticking to their Buy rating on the biotech while raising their price target on its stock to $11 from $9.

Fresh data supports the potential of the company’s proprietary C1 platform – a fungal expression technology for producing enzymes – which helps bring biologic vaccines, therapeutic enzymes, proteins, biosimilars and drugs to market faster and at a lower cost.

READ: Dyadic International 'chock-full' of catalysts, says Dawson James Securities

Indeed, the Noble team is particularly impressed by new evidence provided by Dyadic’s research partner VTT Technical Research Centre of Finland (VTT), which shows the building block for hyman glycan is produced by the C1 platform. “We think this is a key milestone for the company to validate the C1 platform in bioproduction,” wrote Noble analysts in a note.

“Glycoengineering is crucial in drug development, as glycans have marked effects on stability, activity, antigenicity and pharmacodynamics. Therefore, glycoengineering to produce human-like proteins is one of the biggest milestones for Dyadic,” the Noble team added.

Currently, over half of biologics, which are expected to see sales of over $300 billion by 2022, are glycoproteins, according to Noble’s report.

“We see upside as the company validates its C1 expression system expanding to multiple biologics markets,” the Noble team concluded. “We are reiterating our Outperform rating on the stock.”

Dyadic has patented its proprietary filamentous fungus, Myceliophthora thermophila, and the associated molecular tools used to engineer the C1 cells to express and manufacture large volumes of low-cost biologic products such as enzymes and proteins. The C1 fungus is a living cell that has been bioengineered by Dyadic scientists for more than two decades.

Quick facts: Dyadic International Inc

Price: 5.99 USD

Market: NASDAQ
Market Cap: $164.54 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...



Full interview: Dyadic paves the way for patients to gain access to low-cost...

Dyadic (NASDAQ) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus.  Emalfarb also telling...

on 1/4/20

2 min read